Onno W Akkerman
Overview
Explore the profile of Onno W Akkerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
1122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dekkers B, Kerstjens H, Breisnes H, Leeming D, Anthony R, Frijlink H, et al.
J Infect Dis
. 2025 Feb;
PMID: 39932906
Background: Adjunctive host-directed therapies are investigated that modulate host immune responses to reduce excessive inflammation and prevent tissue damage in tuberculosis (TB). Macrolides, including azithromycin, were shown to possess anti-inflammatory...
2.
Garcia-Prats A, Garcia-Cremades M, Cox V, Kredo T, Dunbar R, Schaaf H, et al.
Lancet Child Adolesc Health
. 2025 Jan;
9(2):100-111.
PMID: 39855750
Background: There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially with more recently available drugs and regimens. We aimed to...
3.
Vogensen V, Singh S, Allende C, Engelthaler D, Boorgula G, Thomas T, et al.
Antimicrob Agents Chemother
. 2025 Jan;
69(2):e0108424.
PMID: 39817762
The impact of heteroresistance on tuberculosis (TB) treatment outcomes is unclear, as is the role of different rifampin and isoniazid exposures on developing resistance mutations. Hollow fiber system model of...
4.
Saktiawati A, Vasiliu A, Saluzzo F, Akkerman O
Pathogens
. 2025 Jan;
13(12).
PMID: 39770305
The global burden of drug-resistant tuberculosis (DR-TB) continues to challenge healthcare systems worldwide. There is a critical need to tackle DR-TB by enhancing diagnostics and drug susceptibility testing (DST) capabilities,...
5.
Akkerman O, Migliori G, Falzon D, Garcia-Basteiro A, Kanchar A, Konstantynovska O, et al.
Eur Respir J
. 2024 Nov;
64(6).
PMID: 39542460
No abstract available.
6.
Hermans S, Akkerman O, Meintjes G, Grobusch M
Infection
. 2024 Jul;
52(5):2083-2095.
PMID: 38955990
Paradoxical reactions (PR) to tuberculosis (TB) treatment are common during treatment, but have also been described after treatment. A presentation with recurrent signs or symptoms of TB after cure or...
7.
Eskandari S, Akkerman O
Lancet Infect Dis
. 2024 Apr;
24(5):e343.
PMID: 38670683
No abstract available.
8.
Post A, Bathoorn E, Postma D, Slebos D, Akkerman O
Infection
. 2024 Apr;
52(4):1481-1488.
PMID: 38589747
Purpose: Bronchoalveolar lavage is commonly used in clinical practice for unresolved pneumonia. However, bronchoalveolar lavage is not suitable for all patients as it is an invasive procedure and can worsen...
9.
Keutzer L, Mockeliunas L, Sturkenboom M, Bolhuis M, Akkerman O, Simonsson U
Pharmaceuticals (Basel)
. 2023 Nov;
16(11).
PMID: 38004440
Long-term usage of linezolid can result in adverse events such as peripheral neuropathy, anemia and thrombocytopenia. Therapeutic drug monitoring data from 75 drug-resistant tuberculosis patients treated with linezolid were analyzed...
10.
van Gemert J, Ravensbergen S, Verschuuren E, Kerstjens H, Willemse B, van Ingen J, et al.
Transplant Rev (Orlando)
. 2023 Oct;
37(4):100800.
PMID: 37832509
Background: There is lack of consensus on non-tuberculous mycobacteria pulmonary disease (NTM-PD) treatment regimen and duration in patient listed for lung transplantation (LTx). We conducted a systematic review on treatment...